Thursday, December 20, 2012 8:29:21 AM
Re DVAX: No offense, but after last month's ADCOM, there's almost no chance of FDA approval this time around.
Yes, you could play a possible bounce off of misguided expectations (that's half of biotech investing!
) but if someone actually thinks that Heplisav is going to be approved they're in for a letdown.
Best of luck.
Yes, you could play a possible bounce off of misguided expectations (that's half of biotech investing!
) but if someone actually thinks that Heplisav is going to be approved they're in for a letdown. Best of luck.
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
